|
1. Sobocki P, Ekman M, Agren H, etal. Model to assess the cost-effectiveness of new treatments for depression. IntJ Technol Assess Health Care 2006; 22: 469-77 2. Casciano R, Arikian SR, TarrideJE, Casciano J, Doyle JJ: Antidepressant selection for major depressivedisorder: the budgetary impact on managed care. Drug Benefit Trends 2000,12(5):6BH-17BH. 3. Malone DC: A budget-impact andcost-effectiveness model for secondline treatment of major depression. J ManagCare Pharm 2007, 13:S8-S18. 4. Perlis RH, Patrick A, SmollerJW, Wang PS: When is pharmacogenetic testing for antidepressant response readyfor the clinic? A costeffectiveness analysis based on data from the STAR*Dstudy (provisional abstract). Neuropsychopharmacology 2009, 34:2227-2236.
|